Investing in Biotech from Horizon 3 Biotech

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode, Matt is joined by Dr Michelle Miller -  CEO and MD at Biotron Limited & Scott Power - Investment Analyst at Morgans & Horizon 3 Biotech Investment Community Member.

Hosted by Horizon 3 Biotech Chief Investment Committee Member Dr Tam Nguyen. In this episode, Tam is joined by Dr Serena Duchi - Senior Research Fellow. Surgery at St Vincent's Hospital & Dr Ross MacDonald - Chief Executive Officer and Managing Director at Cynata Therapeutics.

Hosted by Horizon 3 Biotech Chief Investment Committee Member Dr Tam Nguyen. In this episode, Tam is joined by Michelle Gallaher -  Founder & CEO at Opyl Ltd  & Stefan Harrer - Chief Innovation Officer at Digital Health CRC Ltd.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode, Matt is joined by Jackie Fairley -  CEO at Starpharmas & Scott Power - Investment Analyst at Morgans & Horizon 3 Biotech Investment Community Member.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode, Matt is joined by John McCutcheon - President & CEO at President and CEO at EBR Systems & Elyse Shapiro - Healthcare Analyst at from Canaccord Genuity.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode, Matt is joined by Dr Megan Baldwi - CEO and Managing Director at Opthea Limited & Daniel Sharp from Canaccord Genuity, one of the most experienced biotech fundraisers in the Australian Market.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt is joined by Amir Zalcenstein - Managing Director at CNJ Ventures & Leslie Chong - Chief Executive Officer and Managing Director at Imugene Limited.

Mike and Ben talk about Scott Galloway's theory of the Great Dispersion - the impact of COVID on business models like direct-to-consumer and how far they're spreading

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt is joined by Michael Woods of Newburyport Partners, Dr John Melki Director & CEO at Genetic Signatures & Dr Paul Gavin - CEO of Avecho Biotechnologies.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara In this episode Matt will be joined by Scott Power of Morgans and Jon Pilcher, CEO of Neuren Pharmaceuticals.

This podcast accompanies Horizon 3 Biotech's BioBullets email for the 13th August 2021

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara In this episode Matt will be joined by Dirk van Dissel of Candour Advisory and Chris Baldwin, Deputy CEO and Chief Commercial Officer of Exopharm.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara In this episode Matt will be joined by Dr Deborah Rathjen, CEO of Carina Biotech and Simon Davidson, Partner at Lander & Rogers

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara In this episode Matt will be joined by Rosemary Cummins of NXT Financial and Ralph Highnam of Volpara Health Technologies.

A chance to meet with Mike, Horizon 3's Executive Chairman, and Matt, the Chief Investment Officer, as they talk about Horizon 3's origins, who its right for and what makes the fund distinctive.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt will be joined by Tony Locantro from Alto Capital and Sue MacLeman who serves in a number of roles with various organisations and companies. 

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. Matt MacNamara, Chief Investment Officer at Horizon 3 Biotech &  Scott Power, Investment Committee at Horizon 3 Biotech.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt will be joined by Horizon 3 Biotech Life Sciences and Capital Markets Executive Dr Graeme Wald and Investment Analyst Scott Power who will be sharing topical investment strategies.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt will be joined by Opthea CEO & Managing Director Dr Megan Baldwin and Phamaxis CEO Gary Phillips.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. Matt & Scott Power, Investment Committee at Horizon 3 Biotech, discuss the origins of the Horizon 3 fund, what drives investment decisions and some of Scott's recommendations for investment in the coming months

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. Matt & Scott Power speak to Dr Nina Webster from Dimerix and CEO & MD Dr Matthijs Smith of Crucible Investments.

Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt will be joined by Investment Analyst Scott Power at Morgans to discuss healthcare investment and the outlook for 2021. Malcolm McColl, CEO & Co-Founder of ImmVirX will also join the panel to discuss his experience at Viralytics and what he is now working on.